SUCCESSFUL COMPLETION OF PLANNED IDMC REVIEW OF ACTION3 PHASE 3 FSGS KIDNEY TRIAL •The sixth scheduled Independent Data Monitoring Committee (IDMC) review, evaluating the available study data for participant safety, study conduct and progress, has been successfully completed • The IDMC recommends the ACTION3 clinical trial continue unchanged, with no changes to design or safety monitoring • The IDMC has again noted no safety concerns to date, consistent with their prior reviews and the existing and emerging strong safety profile of DMX-200 • The next scheduled IDMC meeting is planned for Q4/2025
Excellent, however the dangers of "cut and paste" later in the doco.
"The study protocol for the ACTION3 clinical trial includes oversight by an IDMC as well as provision for interim safety reviews, the fifth of which has now been successfully completed."
DXB Price at posting:
59.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)